enGene to Participate in Upcoming Investor Conferences
Business Wire•06/11/2026•08:00 ET
0
Key Highlights
- ➤enGene management to join UBS Global Biopharma Conference fireside chat November 16, 2026
- ➤enGene management to join Jefferies Global Healthcare Conference fireside chat November 19, 2026
- ➤Detalimogene undergoing ongoing multi-cohort LEGEND Phase 2 trial for NMIBC
- ➤Pivotal cohort targets high-risk BCG-unresponsive bladder cancer patients with CIS
enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company today announced that management will participate in the following investor conferences:
A live webcast of these events can be accessed on the “Events and Presentations” page under the “Investors” section of the enGene website at www.engene.com and will be archived there for 90 days.
Get started
Create a free account to read the full story.